These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1239 related articles for article (PubMed ID: 28412170)

  • 1. Lipid Nanoparticle Systems for Enabling Gene Therapies.
    Cullis PR; Hope MJ
    Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
    Kulkarni JA; Cullis PR; van der Meel R
    Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
    Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
    J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.
    Hsu SH; Yu B; Wang X; Lu Y; Schmidt CR; Lee RJ; Lee LJ; Jacob ST; Ghoshal K
    Nanomedicine; 2013 Nov; 9(8):1169-80. PubMed ID: 23727126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
    Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
    J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma.
    Makita Y; Murata S; Katou Y; Kikuchi K; Uejima H; Teratani M; Hoashi Y; Kenjo E; Matsumoto S; Nogami M; Otake K; Kawamata Y
    Biochem Biophys Res Commun; 2017 Nov; 493(1):800-806. PubMed ID: 28843857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
    Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
    Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference. Drugging RNAi.
    Haussecker D; Kay MA
    Science; 2015 Mar; 347(6226):1069-70. PubMed ID: 25745148
    [No Abstract]   [Full Text] [Related]  

  • 12. On the role of helper lipids in lipid nanoparticle formulations of siRNA.
    Kulkarni JA; Witzigmann D; Leung J; Tam YYC; Cullis PR
    Nanoscale; 2019 Nov; 11(45):21733-21739. PubMed ID: 31713568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma.
    Hajiasgharzadeh K; Somi MH; Shanehbandi D; Mokhtarzadeh A; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3263-3276. PubMed ID: 30362510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid nanoparticle delivery systems for siRNA-based therapeutics.
    Wan C; Allen TM; Cullis PR
    Drug Deliv Transl Res; 2014 Feb; 4(1):74-83. PubMed ID: 25786618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach.
    Li L; Wang R; Wilcox D; Sarthy A; Lin X; Huang X; Tian L; Dande P; Hubbard RD; Hansen TM; Wada C; Zhao X; Kohlbrenner WM; Fesik SW; Shen Y
    Mol Cancer Ther; 2013 Nov; 12(11):2308-18. PubMed ID: 23943805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets.
    Conway A; Mendel M; Kim K; McGovern K; Boyko A; Zhang L; Miller JC; DeKelver RC; Paschon DE; Mui BL; Lin PJC; Tam YK; Barbosa C; Redelmeier T; Holmes MC; Lee G
    Mol Ther; 2019 Apr; 27(4):866-877. PubMed ID: 30902585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells.
    Uemura Y; Naoi T; Kanai Y; Kobayashi K
    Pharm Dev Technol; 2019 Mar; 24(3):263-268. PubMed ID: 29688101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.